Loss of RASSF1A Expression in Colorectal Cancer and Its Association with K-ras Status

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2013 Jul 19

PMID 23865079

Citations 7

Authors

Dan Cao

Ye Chen

Yuan Tang

Xing-Chen Peng

Hang Dong

Long-Hao Li

Ke Cheng

Jun Ge

Ji-Yan Liu

Affiliations

Soon will be listed here.

Abstract

Background: The RAS-association domain family 1 A (RASSF1A) is a classical member of RAS effectors regulating cell proliferation and apoptosis. Loss of RASSF1A expression may shift the balance towards a growth-promoting effect without the necessity of activating K-ras mutations. Its potential association with K-ras mutations in colorectal cancer (CRC) is unclear.

Methods: RASSF1A expression was examined in normal mucosa, adenoma, and tumor tissues of colon and rectum, respectively. We examined the association of RASSF1A expression, mutations of K-ras, and EGFR status in 76 primary CRCs. The relationship between clinicopathological characteristics and RASSF1A expression was also analyzed.

Results: RASSF1A expression level decreased progressively in normal mucosa, adenoma and, tumor tissues, and the loss of RASSF1A expression occurred more frequently in tumor tissues. Of 76 primary CRCs, loss of RASSF1A expression and/or K-ras mutations were detected in 77% cases. Loss of RASSF1A expression was more frequent in K-ras wild-type than in mutation cases (63% versus 32%, P = 0.011).

Conclusions: Our study indicates that loss of RASSF1A may be involved in pathogenesis of CRC, its expression was found predominantly in K-ras wild-type CRCs, suggesting that it may be another way of affecting RAS signaling, in addition to K-ras mutations.

Citing Articles

Deciphering Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Reveals the Poor Prognostic Factor of RASSF2 Gene Silencing in Colon Cancers.

Riffet M, Eid Y, Faisant M, Fohlen A, Menahem B, Alves A Cancers (Basel). 2021; 13(23).

PMID: 34885067 PMC: 8656858. DOI: 10.3390/cancers13235957.

Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.

Nassar F, Msheik Z, Nasr R, Temraz S Clin Epigenetics. 2021; 13(1):111.

PMID: 34001239 PMC: 8130320. DOI: 10.1186/s13148-021-01095-5.

Immunohistochemical Profile of Tumor Suppressor Proteins RASSF1A and LATS1/2 in Relation to p73 and YAP Expression, of Human Inflammatory Bowel Disease and Normal Intestine.

Nterma P, Panopoulou E, Papadaki-Petrou E, Assimakopoulou M Pathol Oncol Res. 2019; 26(1):567-574.

PMID: 30604274 DOI: 10.1007/s12253-018-00575-z.

Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype.

Opinto G, Silvestris N, Centonze M, Graziano G, Pinto R, Fucci L Oncotarget. 2017; 8(50):87782-87794.

PMID: 29152120 PMC: 5675672. DOI: 10.18632/oncotarget.21213.

Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy.

Sun X, Yuan W, Hao F, Zhuang W Med Sci Monit. 2017; 23:5389-5395.

PMID: 29128865 PMC: 5697441. DOI: 10.12659/msm.903927.

References

Azizi E, Kittai A, Kozuch P . Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer. Chemother Res Pract. 2012; 2012:198197. PMC: 3472558. DOI: 10.1155/2012/198197. View

Pfeifer G, Dammann R . Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 2005; 70(5):576-83. DOI: 10.1007/s10541-005-0151-y. View

Miranda E, Destro A, Malesci A, Balladore E, Bianchi P, Baryshnikova E . Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer. 2006; 95(8):1101-7. PMC: 2360724. DOI: 10.1038/sj.bjc.6603337. View

Ogino S, Nosho K, Kirkner G, Kawasaki T, Meyerhardt J, Loda M . CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2008; 58(1):90-6. PMC: 2679586. DOI: 10.1136/gut.2008.155473. View

Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, Iida T . Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. Oncol Rep. 2006; 15(5):1281-5. View

Spugnardi M, Tommasi S, Dammann R, Pfeifer G, Hoon D . Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 2003; 63(7):1639-43. View

Ahlquist T, Bottillo I, Danielsen S, Meling G, Rognum T, Lind G . RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia. 2008; 10(7):680-6, 2 p following 686. PMC: 2434205. DOI: 10.1593/neo.08312. View

Cui X, Shirai Y, Wakai T, Yokoyama N, Hirano S, Hatakeyama K . Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol. 2004; 35(10):1189-95. DOI: 10.1016/j.humpath.2004.06.010. View

Cohen S, Cohen R, Meropol N . Targeting signal transduction pathways in colorectal cancer--more than skin deep. J Clin Oncol. 2005; 23(23):5374-85. DOI: 10.1200/JCO.2005.02.194. View

10.

Cui X, Wakai T, Shirai Y, Hatakeyama K, Hirano S . Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicol Sci. 2006; 91(2):372-81. DOI: 10.1093/toxsci/kfj159. View

11.

Santos E, Reddy E, Pierotti M, Della Porta G, Barbacid M . Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science. 1984; 223(4637):661-4. DOI: 10.1126/science.6695174. View

12.

Yanagawa N, Tamura G, Oizumi H, Endoh M, Sadahiro M, Motoyama T . Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status. Anticancer Res. 2011; 31(4):1211-4. View

13.

Gao B, Xie X, Huang C, Shames D, Chen T, Lewis C . RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008; 68(1):22-5. PMC: 2833356. DOI: 10.1158/0008-5472.CAN-07-5183. View

14.

Goldstein N, Armin M . Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001; 92(5):1331-46. DOI: 10.1002/1097-0142(20010901)92:5<1331::aid-cncr1455>3.0.co;2-m. View

15.

Lo P, Xie D, Chan K, Xu F, Kuzmin I, Lerman M . Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage. Cancer Lett. 2007; 257(2):199-205. DOI: 10.1016/j.canlet.2007.07.018. View

16.

Kee S, Lee J, Kim M, Lee S, Jung Y, Kim Y . Hypermethylation of the Ras association domain family 1A (RASSF1A) gene in gallbladder cancer. Mol Cells. 2008; 24(3):364-71. View

17.

Vos M, Ellis C, Bell A, Birrer M, Clark G . Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem. 2000; 275(46):35669-72. DOI: 10.1074/jbc.C000463200. View

18.

Lee M, Kim H, Byun D, Lee S, Lee C, Kim J . Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res. 2001; 61(18):6688-92. View

19.

Yeo W, Wong W, Wong N, Law B, Tse G, Zhong S . High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer. Pathology. 2005; 37(2):125-30. DOI: 10.1080/00313020500058623. View

20.

Hesson L, Cooper W, Latif F . The role of RASSF1A methylation in cancer. Dis Markers. 2007; 23(1-2):73-87. PMC: 3850810. DOI: 10.1155/2007/291538. View